Friday, November 12, 2021 12:55:54 PM
Shroomz and budz did help me manage the psychologic effects of chemo/cancers. Plenty Other companies are pursuing that too.
I am more satisfied with the dmt use for Stroke and the microdose concepts AGN is pursuing with CMIT.
Also...
Ifenprodil is targeting SCLC tumors and Chronic Cough with NO competition.
I'll stay here.
The bet is 'news' before Nasdaq or a PP. Partnerships and/or grants are a strong possibility, IMO.
Thanks for outside DD on D.MW's ventures after he deserted his obligations here with the disgraceful dec 20 presentation and exit. Probably 'seeing some trends' with those new psyc molecules.
Our Science experts, Yost / D.MW have certainly screwt Shareholders, from Bth to Agn, about our paid for IPs for their personal benefits. Thieves, IMHFO...
We can hope for better commitments and respect for shareholders that invest in AGN IP.
...GLTA...
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM